A phase II multicenter, single-arm, open-label trial of LN 145 for the treatment of patients with recurrent, metastatic or persistent cervical carcinoma

Trial Profile

A phase II multicenter, single-arm, open-label trial of LN 145 for the treatment of patients with recurrent, metastatic or persistent cervical carcinoma

Planning
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs LN 145 (Primary)
  • Indications Cervical cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Sep 2017 New trial record
    • 13 Sep 2017 According to an Iovance Biotherapeutics media release, Clinical Trial Application (CTA) for this trial has been approved by the competent authority (CA) in the Netherlands
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top